Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters.

Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA.

J Neuroimmunol. 2007 May;186(1-2):181-92. Epub 2007 May 2.

PMID:
17477976
2.

The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.

Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LA.

J Psychopharmacol. 2007 Aug;21(6):611-9. Epub 2006 Nov 8.

PMID:
17092975
3.

Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.

Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO.

Bull Exp Biol Med. 2001 Feb;131(2):127-9.

PMID:
11391392
4.

Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M.

J Alzheimers Dis. 2011;26(1):171-9. doi: 10.3233/JAD-2011-110221.

PMID:
21593566
5.

Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates.

van Helmond Z, Heesom K, Love S.

J Neurosci Methods. 2009 Jan 30;176(2):206-12. doi: 10.1016/j.jneumeth.2008.09.002. Epub 2008 Sep 6.

PMID:
18824027
6.

Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects.

Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E.

Neurosci Lett. 2004 Jan 30;355(3):226-30.

PMID:
14732472
7.

Specific reactivity of mild/severe Alzheimer's disease patient's sera to antibody against Abeta1-40 epitope 17-21.

Bolukbasi Hatip FF, Matsunaga Y, Yamada T.

Acta Neurol Scand. 2008 Jun;117(6):404-8. Epub 2007 Nov 13.

PMID:
18005218
8.

Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.

Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL.

Protein Eng Des Sel. 2009 Mar;22(3):199-208. doi: 10.1093/protein/gzn052. Epub 2008 Oct 16.

PMID:
18927231
9.

Autoantibodies to amyloid-beta and Alzheimer's disease.

Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R.

Ann Neurol. 2001 Jun;49(6):808-10.

PMID:
11409436
10.

Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ.

Neurochem Int. 2001 Nov-Dec;39(5-6):409-13.

PMID:
11578776
11.

Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease.

Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK.

J Neurosci. 2008 Dec 17;28(51):13805-14. doi: 10.1523/JNEUROSCI.4218-08.2008.

12.

Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.

Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M.

Brain Res. 2008 Jul 11;1219:169-79. doi: 10.1016/j.brainres.2008.02.060. Epub 2008 Mar 4.

PMID:
18534566
13.

Oligomeric amyloid beta-protein as a therapeutic target in Alzheimer's disease: its significance based on its distinct localization and the occurrence of a familial variant form.

Ito K, Ishibashi K, Tomiyama T, Umeda T, Yamamoto K, Kitajima E, Idomoto T, Nagatomo T, Mori H.

Curr Alzheimer Res. 2009 Apr;6(2):132-6.

PMID:
19355847
14.

Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.

Hashimoto M, Shahdat HM, Yamashita S, Katakura M, Tanabe Y, Fujiwara H, Gamoh S, Miyazawa T, Arai H, Shimada T, Shido O.

J Neurochem. 2008 Dec;107(6):1634-46. doi: 10.1111/j.1471-4159.2008.05731.x. Epub 2008 Nov 5.

15.

Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.

Meli G, Visintin M, Cannistraci I, Cattaneo A.

J Mol Biol. 2009 Apr 3;387(3):584-606. doi: 10.1016/j.jmb.2009.01.061. Epub 2009 Feb 4.

PMID:
19361429
16.

Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?

Funke SA, Birkmann E, Willbold D.

Curr Alzheimer Res. 2009 Jun;6(3):285-9. Review.

PMID:
19519310
17.

Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes.

Mruthinti S, Schade RF, Harrell DU, Gulati NK, Swamy-Mruthinti S, Lee GP, Buccafusco JJ.

Curr Alzheimer Res. 2006 Jul;3(3):229-35.

PMID:
16842100
19.

Serum levels of S100B and NSE proteins in Alzheimer's disease patients.

Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV.

J Neuroinflammation. 2010 Jan 27;7:6. doi: 10.1186/1742-2094-7-6.

20.

Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression.

Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D.

J Alzheimers Dis. 2012;32(1):95-100.

PMID:
22766733

Supplemental Content

Support Center